GoAI
Get started
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc

KNSA

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$79.03

+$0.56 · +0.71%

Aug 21, 4:00 PM ET

Pre-market

$79.50

+$0.47 · +0.59%

Aug 24, 4:01 AM ET

KNSA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

79

Undervalued

Momentum

70

Gaining

Sentiment

66

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
GB
CEO
Sanj K. Patel
Listed since
May 24, 2018
Employees
366

Market position

Day range

Current $79.03

52-week range

Current $79.03

Open
$78.655
Previous close
$78.47
Volume
270.12K
0.35× average
Average volume
764.93K
Average daily volume
Market cap
6.02B USD
Beta
0.09
Market reference 1
50-day average
$67.0266
+17.91% above average
200-day average
$50.906
+55.25% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.9B USD
P/E (TTM)
73.86×
P/B (TTM)
9.37×
P/S (TTM)
7.16×
EV / EBITDA
32.12×
Earnings yield
1.93%
Free cash flow yield
0.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.49%
Operating margin
11.92%
Net margin
9.59%
Return on equity
10.40%
Return on assets
7.73%
Return on invested capital
8.17%

Financial health

Debt / equity
0.01×
Current ratio
3.79×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends140%-60%-260%-460%Gross margin, FY2021: 76.39%Gross margin, FY2022: 89.60%Gross margin, FY2023: 79.09%Gross margin, FY2024: 85.61%Gross margin, FY2025: 54.63%Operating margin, FY2021: -406.38%Operating margin, FY2022: 4.44%Operating margin, FY2023: -9.32%Operating margin, FY2024: -10.78%Operating margin, FY2025: 11.40%Net margin, FY2021: -409.72%Net margin, FY2022: 83.28%Net margin, FY2023: 5.21%Net margin, FY2024: -10.21%Net margin, FY2025: 8.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 76.39%. Gross margin FY2022 89.60%. Gross margin FY2023 79.09%. Gross margin FY2024 85.61%. Gross margin FY2025 54.63%. Operating margin FY2021 -406.38%. Operating margin FY2022 4.44%. Operating margin FY2023 -9.32%. Operating margin FY2024 -10.78%. Operating margin FY2025 11.40%. Net margin FY2021 -409.72%. Net margin FY2022 83.28%. Net margin FY2023 5.21%. Net margin FY2024 -10.21%. Net margin FY2025 8.71%.

Income trends

Revenue

677.56M USD+60.09%

Operating income

77.22M USD+122.84M USD

Net income

59.01M USD+102.2M USD
Income trends across reported periods761.11M USD426.92M USD92.72M USD−241.47M USDRevenue, FY2021: 38.54M USDRevenue, FY2022: 220.18M USDRevenue, FY2023: 270.26M USDRevenue, FY2024: 423.24M USDRevenue, FY2025: 677.56M USDOperating income, FY2021: −156.64M USDOperating income, FY2022: 9.77M USDOperating income, FY2023: −25.2M USDOperating income, FY2024: −45.62M USDOperating income, FY2025: 77.22M USDNet income, FY2021: −157.92M USDNet income, FY2022: 183.36M USDNet income, FY2023: 14.08M USDNet income, FY2024: −43.19M USDNet income, FY2025: 59.01M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 38.54M USD. Revenue FY2022 220.18M USD. Revenue FY2023 270.26M USD. Revenue FY2024 423.24M USD. Revenue FY2025 677.56M USD. Operating income FY2021 −156.64M USD. Operating income FY2022 9.77M USD. Operating income FY2023 −25.2M USD. Operating income FY2024 −45.62M USD. Operating income FY2025 77.22M USD. Net income FY2021 −157.92M USD. Net income FY2022 183.36M USD. Net income FY2023 14.08M USD. Net income FY2024 −43.19M USD. Net income FY2025 59.01M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue677.56M USD423.24M USD270.26M USD220.18M USD38.54M USD
Cost of goods sold307.41M USD60.91M USD56.52M USD22.9M USD9.1M USD
Gross profit370.15M USD362.33M USD213.74M USD197.29M USD29.44M USD
Research and development96.85M USD111.62M USD76.1M USD65.49M USD99.3M USD
Selling, general, and administrative196.27M USD168.01M USD129.43M USD97.95M USD85.95M USD
Operating expenses292.93M USD407.95M USD238.93M USD187.51M USD186.08M USD
Interest income11.65M USD9.46M USD8.54M USD1.25M USD97K USD
Depreciation and amortization1.55M USD1.7M USD2.34M USD2.4M USD2.36M USD
Operating income77.22M USD−45.62M USD−25.2M USD9.77M USD−156.64M USD
Net income59.01M USD−43.19M USD14.08M USD183.36M USD−157.92M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.75
FY2025
Latest fiscal-year revenue
677.56M USD
FY2025 · +60.09% year over year
Next fiscal-year EPS consensus
1.39
FY2026 · 4 analysts
Next fiscal-year revenue consensus
993.65M USD
FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend4.011.72-0.58-2.87FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend1.6B1.03B465.45M-103.76MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$86.40

9.33% upside
Past 12 months12-month forecastHigh $99.00Average $86.40Low $71.00

Rating distribution

11 ratings
Strong buy00%
Buy11100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

8 institutions

KNSA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KNSA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
98.43M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
84.42M
Weight
0.10%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
71.23M
Weight
0.04%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
41.14M
Weight
0.09%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
31.07M
Weight
0.21%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
17.68M
Weight
0.10%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
11.88M
Weight
0.08%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
11.48M
Weight
0.14%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research KNSA

research.disclaimer